

Case of COVID mRNA Vaccine linked Antiphospholipid Syndrome

Dr. Eduardo J Balbona

ebalbona@bellsouth.net

Case Report

Keywords: SARS-CoV-2, COVID-19 mRNA vaccination, Pulmonary embolism, Antiphospholipid Syndrome, Thrombosis, Autoimmune, Hypercoagulable State, DVT, PE

Posted Date: April 20th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1574234/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

EDITORIAL NOTE:

25 March, 2024. Expression of Concern. "Case of COVID mRNA Vaccine linked Antiphospholipid Syndrome" The case report, while addressing a potentially significant health issue, is notably brief and lacks detailed clinical data, making its claims about the negative effects of mRNA vaccines on insufficient grounds. The potential for misinterpretation of these findings, especially in the current global context, is high and could lead to public health concerns. The paper has not undergone formal peer review, which is vital for ensuring the reliability of medical research. We emphasize the need for cautious interpretation of these preliminary findings and recommend further research and peer-reviewed studies for more conclusive evidence.

A Case of COVID mRNA Vaccine linked to antiphospholipid syndrome

E.J. Balbona M.D. Art of Medicine PA

April 13th 2022

There have been several reports of thrombotic adverse events after administration of the mRNA COVID vaccine [1] [2]. The onset of autoimmune disease has also been reported following viral illness as well as following vaccination [3]. The antiphospholipid syndrome is an autoimmune hypercoagulable state that can result in thrombotic events such as deep venous thrombosis, pulmonary embolus, and stroke [4]. The antiphospholipid syndrome has also been reported following natural Covid infection [5]. Herein we present a case of “antiphospholipid syndrome” following COVID mRNA vaccination and associated with life threatening thrombosis.

A 22-year-old male in otherwise excellent health is recommended a Covid vaccination. Subsequently, he suffers a large pulmonary embolus requiring hospitalization. He has no history of trauma, immobility, or medical risk factors for venous thrombosis. He is also on no culprit medications, has no history of drug use and no family history of hypercoagulability. The antiphospholipid antibody: anti-cardiolipin IgG is found to be greater than ten times that of normal. The anticardiolipin antibody level being greater than 150 gpl, normal being less than 14 gpl. Per guidelines these values are repeated and remain markedly elevated (greater than 150 gpl), thus confirming the “antiphospholipid syndrome.” His anti-cardiolipin IgM antibodies are noted to also be elevated supporting the recent development of these antiphospholipid antibodies. Notably his Covid nucleocapsid antibodies are negative for prior natural COVID infection or exposure. [6]

The repeatedly positive anti phospholipid antibodies confirm the hypercoagulable syndrome. The findings suggest a possible autoimmune reaction to the COVID mRNA vaccine. Autoimmune and complement abnormalities have previously been reported after mRNA vaccination [7]. This may have implications for the many new medications currently being designed to be delivered by similar means.

The case suggests the induction of an autoimmune disorder that can result in thrombophilia and a possible mechanism for thrombotic complications following exposure to mRNA therapies.

Acknowledgments

Financial support. The author(s) received no financial support for the research, authorship, and/or publication of this article.

Potential conflicts of interest. No conflicts of interests were declared by any of the authors listed. All authors: no reported conflicts of interest.

Patient consent. Written consent was obtained from the patient for the case report.

References

- [1] Marie Joelle Jabagi, PharmD, PhD1; Jérémie Botton, PharmD, PhD1; Marion Bertrand, MSc1; et alAlain Weill, MD1; Paddy Farrington, PhD2; Mahmoud Zureik, MD, PhD1; Rosemary Dray-Spira, MD, PhD Myocardial Infarction, Stroke, and Pulmonary Embolism After BNT162b2 mRNA COVID-19 Vaccine... JAMA. 2022;327(1):80-82. doi:10.1001/jama.2021.21699
- [2] David M. Smadja,1,2,3 Qun-Ying Yue,4 Richard Chocron,5 Olivier Sanchez,1,3,6 and Agnes Lillo-Le Louet1,7 Vaccination against COVID-19: insight from arterial and venous thrombosis occurrence using data from VigiBase [Eur Respir J.](#) 2021 Jul; 58(1): 2100956. Published online 2021 Jul 1. doi: [10.1183/13993003.00956-2021](https://doi.org/10.1183/13993003.00956-2021) PMID: [33863748](https://pubmed.ncbi.nlm.nih.gov/33863748/) PMCID: PMC8051185
- [3] Cohen AD, Shoenfeld Y.. Vaccine-induced autoimmunity. J Autoimmun. 1996;9(6):699-703. – PubMed
- [4] NINDS Antiphospholipid Syndrome Information Page. National Institute of Neurological Disorders and Stroke. June 30, 2015; <https://www.ninds.nih.gov/Disorders/All-Disorders/Antiphospholipid-Syndrome-Information-Page>.
- [5] Bertin et al., Persistent IgG anticardiolipin autoantibodies are associated with post-COVID syndrome Int. J. Infect. Dis. (2021 Dec 1)
- [6] Ryan Thomas, MD; Samer Albahra, MD; Scott Bainbridge, CLS; Nam K Tran, PhD - Role of Quantitative Serology Testing for COVID-19. UC Davis Health Blog Labs Best Practice August 23rd 2021 ; <https://health.ucdavis.edu/blog/lab-best-practice/role-of-quantitative-serology-testing-for-covid-19/2021/08>
- [7] Andrew Jay Portuguese 1, Cassandra Sunga 2, Rebecca Kruse-Jarres 1 3, Terry Gernsheimer 1, Janis Abkowitz, Autoimmune- and complement-mediated hematologic condition recrudescence following SARS-CoV-2 vaccination PMID: 34255033 PMCID: PMC8276576 DOI: [10.1182/bloodadvances.2021004957](https://doi.org/10.1182/bloodadvances.2021004957)